Hubei Biocause Pharmaceutical (000627) — Net Asset Momentum
Hubei Biocause Pharmaceutical (000627) recorded a net asset momentum of -2.8% as of December 2023, with net assets of CN¥33.63 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See how many days can Hubei Biocause Pharmaceutical fund operations to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Hubei Biocause Pharmaceutical Net Asset Momentum (2000–2023)
This chart tracks Hubei Biocause Pharmaceutical's year-over-year net asset growth across 24 annual reporting periods from 2000 to 2023. The most recent momentum reading is -2.8%, with net assets of CN¥33.63 Billion CNY as of December 2023. Read Hubei Biocause Pharmaceutical debt and liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for Hubei Biocause Pharmaceutical (2000–2023)
The table below shows the complete annual net asset history for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see 000627 market cap overview.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2023 | CN¥33.63 Billion | CN¥301.94 Billion | CN¥268.30 Billion | ▼ -2.8% |
| 2022 | CN¥34.60 Billion | CN¥288.60 Billion | CN¥254.00 Billion | ▼ -7.7% |
| 2021 | CN¥37.47 Billion | CN¥263.90 Billion | CN¥226.43 Billion | ▲ +8.3% |
| 2020 | CN¥34.59 Billion | CN¥239.40 Billion | CN¥204.81 Billion | ▲ +0.7% |
| 2019 | CN¥34.35 Billion | CN¥205.27 Billion | CN¥170.92 Billion | ▲ +32.1% |
| 2018 | CN¥26.01 Billion | CN¥178.25 Billion | CN¥152.24 Billion | ▼ -2.6% |
| 2017 | CN¥26.70 Billion | CN¥140.42 Billion | CN¥113.71 Billion | ▲ +30.9% |
| 2016 | CN¥20.40 Billion | CN¥117.88 Billion | CN¥97.48 Billion | ▲ +1043.5% |
| 2015 | CN¥1.78 Billion | CN¥2.41 Billion | CN¥625.50 Million | ▲ +19.7% |
| 2014 | CN¥1.49 Billion | CN¥2.11 Billion | CN¥618.76 Million | ▲ +3.7% |
| 2013 | CN¥1.44 Billion | CN¥2.16 Billion | CN¥720.71 Million | ▼ -6.6% |
| 2012 | CN¥1.54 Billion | CN¥2.06 Billion | CN¥527.37 Million | ▲ +8.7% |
| 2011 | CN¥1.41 Billion | CN¥1.88 Billion | CN¥469.47 Million | ▼ -11.7% |
| 2010 | CN¥1.60 Billion | CN¥1.98 Billion | CN¥374.25 Million | ▲ +1.8% |
| 2009 | CN¥1.57 Billion | CN¥2.16 Billion | CN¥581.29 Million | ▲ +4.1% |
| 2008 | CN¥1.51 Billion | CN¥1.98 Billion | CN¥466.75 Million | ▲ +74.7% |
| 2007 | CN¥866.03 Million | CN¥1.32 Billion | CN¥458.52 Million | ▲ +19.7% |
| 2006 | CN¥723.71 Million | CN¥1.17 Billion | CN¥443.66 Million | ▼ -1.0% |
| 2005 | CN¥731.23 Million | CN¥1.09 Billion | CN¥356.70 Million | ▲ +1.0% |
| 2004 | CN¥723.91 Million | CN¥1.08 Billion | CN¥357.41 Million | ▲ +0.7% |
| 2003 | CN¥718.75 Million | CN¥1.09 Billion | CN¥372.22 Million | ▼ -6.4% |
| 2002 | CN¥768.02 Million | CN¥1.09 Billion | CN¥322.39 Million | ▲ +0.7% |
| 2001 | CN¥762.99 Million | CN¥989.09 Million | CN¥226.09 Million | ▲ +28.3% |
| 2000 | CN¥594.52 Million | CN¥886.33 Million | CN¥291.81 Million | — |